Clinical Trials
19 trialsNCT04897321 2026-05-19
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT04539366 2026-05-13
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
National Cancer Institute (NCI)
Phase 1 Suspended
NCT01953900 2026-04-22
VEGAS
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05849662 2026-04-15
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1/2 Recruiting
NCT01822652 2026-04-06
GRAIN
Baylor College of Medicine
Phase 1 Active not recruiting
NCT04119024 2026-03-17
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Phase 1 Recruiting
NCT06186401 2026-03-16
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
University of California, San Francisco
Phase 1 Recruiting
NCT07358260 2026-01-22
B7-H3.CD28Z.CART in Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT04530487 2025-06-29
Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04521946 2024-10-26
Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT02774291 2023-08-04
Anti-NY ESO-1 mTCR Peripheral Blood Lymphocytes
Albert Einstein College of Medicine
Phase EARLY_PHASE1 Terminated
NCT05303727 2022-07-01
Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Not yet recruiting
NCT01967823 2021-03-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00698009 2020-09-24
Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01454596 2019-08-21
CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00801931 2019-03-27
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Columbia University
Phase 1/2 Terminated
NCT00670410 2016-06-24
Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma
Columbia University
Phase 1 Terminated
NCT00874315 2015-10-16
Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed or Refractory High-Risk NBL.
Nationwide Children's Hospital
Phase 2 Withdrawn
NCT00084695 2014-01-10
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
National Cancer Institute (NCI)
Phase 2 Unknown